Gain Therapeutics
Stock Forecast, Prediction & Price Target
Gain Therapeutics Financial Estimates
Gain Therapeutics Revenue Estimates
Gain Therapeutics EBITDA Estimates
Gain Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $164.99K N/A | $140.10K -15.08% | $55.18K -60.61% | Avg: $175K Low: $108.62K High: $241.37K avg. 217.14% | Avg: $112.5K Low: $46.64K High: $171.49K avg. -35.71% | Avg: $225K Low: $93.29K High: $342.98K avg. 100% | Avg: $100.29M Low: $41.58M High: $152.88M avg. 44474.53% |
Net Income
% change YoY
| $-13.89M N/A | $-17.59M -26.63% | $-22.26M -26.58% | Avg: $-28.24M Low: $-17.04M High: $-11.05M avg. -26.82% | Avg: $-38.77M Low: $-21.07M High: $-17.43M avg. -37.29% | Avg: $-19.97M Low: $-33.58M High: $-4.77M avg. 48.48% | Avg: $-1.95M Low: $-3.28M High: $-466.50K avg. 90.22% |
EBITDA
% change YoY
| $-13.75M N/A | $-17.68M -28.55% | $-22.16M -25.38% | Avg: $-175K Low: $-241.37K High: $-108.62K avg. 99.21% | Avg: $-112.5K Low: $-171.49K High: $-46.64K avg. 35.71% | Avg: $-225K Low: $-342.98K High: $-93.29K avg. -100% | Avg: $-100.29M Low: $-152.88M High: $-41.58M avg. -44474.53% |
EPS
% change YoY
| -$1.37 N/A | -$1.48 -8.02% | -$1.71 -15.54% | Avg: -$1.13 Low: -$1.31 High: -$0.85 avg. 33.68% | Avg: -$1.48 Low: -$1.62 High: -$1.34 avg. -30.51% | Avg: -$1.54 Low: -$2.58 High: -$0.37 avg. -3.71% | Avg: -$0.15 Low: -$0.25 High: -$0.04 avg. 90.22% |
Operating Expenses
% change YoY
| $13.99M N/A | $17.91M 28.06% | $22.30M 24.50% | Avg: $12.62M Low: $7.83M High: $17.41M avg. -43.38% | Avg: $8.11M Low: $3.36M High: $12.37M avg. -35.71% | Avg: $16.23M Low: $6.73M High: $24.75M avg. 100.00% | Avg: $7.23B Low: $3.00B High: $11.03B avg. 44474.53% |
FAQ
What is Gain Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 18.64% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -17.04M, average is -28.24M and high is -11.05M.
What is Gain Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 11188.99% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $108.62K, average is $175K and high is $241.37K.
What is Gain Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 22.42% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$1.31, average is -$1.13 and high is $-0.85.
What is the best performing analyst?
In the last twelve months analysts have been covering Gain Therapeutics stock. The most successful analyst is Thomas Shrader.